Literature DB >> 21420870

Sodium mercaptoundecahydro-closo-dodecaborate (BSH), a boron carrier that merits more attention.

Andrea Wittig1, Finn Stecher-Rasmussen, Ralf A Hilger, Jürgen Rassow, Pierluigi Mauri, Wolfgang Sauerwein.   

Abstract

Boron neutron capture therapy relies on the preferential delivery of a (10)B-compound to tumor cells. The BSH-biodistribution was investigated in nu/nu mice and human patients. The boron concentration was measured with prompt gamma ray spectroscopy. BSH accumulates to a very low extent not only in brain, but also in fat tissue, bone and muscle, which makes BSH an interesting drug not only for brain lesions but also for tumors located at the extremities. The differential uptake in different organs indicates a complex mechanism. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21420870     DOI: 10.1016/j.apradiso.2011.02.046

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

Review 1.  Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.

Authors:  Micah John Luderer; Pilar de la Puente; Abdel Kareem Azab
Journal:  Pharm Res       Date:  2015-06-02       Impact factor: 4.200

2.  Intracavitary moderator balloon combined with (252)Cf brachytherapy and boron neutron capture therapy, improving dosimetry in brain tumour and infiltrations.

Authors:  S F Brandão; T P R Campos
Journal:  Br J Radiol       Date:  2015-04-30       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.